[tabs]
[tab title=”2010″]
1. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ; AQUAMAT group.Lancet. 2010 Nov 13;376(9753):1647-57. doi: 10.1016/S0140-6736(10)61924-1. Epub 2010 Nov 7. Erratum in: Lancet. 2011 Jan 8;377(9760):126.[Read more>>]
2. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Hietala SF, Mårtensson A, Ngasala B, Dahlström S, Lindegårdh N, Annerberg A, Premji Z, Färnert A, Gil P, Björkman A, Ashton M.Antimicrob Agents Chemother. 2010 Nov;54(11):4780-8. doi: 10.1128/AAC.00252-10. Epub 2010 Aug 16.[Read more>>]
3. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh CM, Nuortti M, Séchaud R, Kaiser G, Lefèvre G.Malar J. 2010 Sep 3;9:253. doi: 10.1186/1475-2875-9-253.[Read more>>]
4. Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting. Kabanywanyi AM, Mulure N, Migoha C, Malila A, Lengeler C, Schlienger R, Genton B.Malar J. 2010 Jul 14;9:205. doi: 10.1186/1475-2875-9-205.[Read more>>]
5. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T.Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.[Read more>>]
6. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, Hashim R, Kaur H, Lemnge M, Mosha FW, Greenwood B, Chandramohan D.PLoS One. 2010 Mar 1;5(3):e9467. doi: 10.1371/journal.pone.0009467.[Read more>>]
7. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B.Malar J. 2010 Feb 11;9:48. doi: 10.1186/1475-2875-9-48.[Read more>>]
8. Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? Ogutu B, Tiono AB, Makanga M, Premji Z, Gbadoé AD, Ubben D, Marrast AC, Gaye O.Malar J. 2010 Jan 22;9:30. doi: 10.1186/1475-2875-9-30.[Read more>>]
[/tab]
[tab title=”2009″]
1. Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.Hodel EM, Kabanywanyi AM, Malila A, Zanolari B, Mercier T, Beck HP, Buclin T, Olliaro P, Decosterd LA, Genton B.PLoS One. 2009 Dec 14;4(12):e8184. doi: 10.1371/journal.pone.0008184.[Read more>>]
2. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE.Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9027-32. doi: 10.1073/pnas.0901415106. Epub 2009 May 18.[Read more>>]
3. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581.Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D.PLoS One. 2009;4(2):e4569. doi: 10.1371/journal.pone.0004569.[Read more>>]
[/tab]
[tab title=”2008″]
Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania.Massaga JJ, Lusingu JP, Makunde R, Malebo HM, Chile MM, Akida JA, Lemnge MM, Rønn AM, Theander TG, Bygbjerg IC, Kitua AY.Tanzan J Health Res. 2008 Jul;10(3):144-50. [Read more>>]
[/tab]
[tab title=2007]
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S.Malar J. 2007 Nov 11;6:146. [Read more>>]
[/tab]
[tab title=2006]
1. A simple technique for the detection of anti-malarial drug formulations and their presence in human urine. Lugimbana L, Malebo HM, Segeja MD, Akida JA, Malle LN, Lemnge MM.Tanzan Health Res Bull. 2006 Sep;8(3):149-54. [Read more>>]
2. High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. Lemnge M, Alifrangis M, Kafuye MY, Segeja MD, Gesase S, Minja D, Massaga JJ, Rønn AM, Bygbjerg IC.Am J Trop Med Hyg. 2006 Aug;75(2):188-93. [Read more>>]
3. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, Enevold A, Rønn AM, Khalil IF, Warhurst DC, Lemnge MM, Theander TG, Bygbjerg IC.J Infect Dis. 2006 Jun 15;193(12):1738-41. Epub 2006 May 4. [Read more>>]
[/tab]
[/tabs]